Cardiology Pharmaceuticals

NYU’s Atherosclerosis Inflammation Discovery

NYU researchers discovered that AstraZeneca’s saracatinib – an investigational drug originally developed to treat cancer – could slow atherosclerosis progression by addressing inflammation that we know contributes to ASCVD and haven’t figured out how to treat.

The researchers’ path towards discovering saracatinib’s atherosclerosis benefits started with analyzing blood samples from 34 statin-takers with ASCVD and from 24 healthy controls – confirming that plasma from people with atherosclerosis had higher inflammatory signals. 

To find a potential treatment, they used the blood samples to identify which genes are involved in atherosclerosis inflammation, and then searched a pharmaceutical database to find an existing drug that might suppress the genetic processes that create that inflammation.

Their search brought them to saracatinib, which they found had a major impact on inflammation and plaque when they applied the cancer drug to…

  • Human blood and tissue samples — reduced inflammation signaling by over 90%
  • Rabbits — reduced plaque-based inflammation by 97%
  • Mice — reduced cells linked to plaque inflammation by 80%

Those results were strong enough for the authors to conclude that saracatinib has the potential to address inflammation in patients who are already taking lipid-lowering drugs, while proposing new phase 2 trials to test this theory.

Future saracatinib studies might be part of a new wave of research into CVD inflammation, noting that cardio-immunology startup Bitterroot Bio just emerged with a similar mission to address the unsolved aspects of cardiovascular disease inflammation.

The Takeaway

Even though we know that inflammation contributes to ASCVD in ways that are independent from dyslipidemia and high cholesterol, lipid-lowering therapy remains the only pharmacologic option for ASCVD risk reduction, leaving atherosclerosis inflammation untreated. Saracatinib might not prove to be the solution to this problem, but the recent surge in CVD inflammation research and funding suggests that we could be getting closer to a solution.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiac Imaging June 16, 2025

Beyond Hardware: Is AI the Answer to Making Cardiac Imaging more Accessible? June 16, 2025

Sponsored by Philips Healthcare Cardiac imaging has traditionally improved through hardware advances, enabling the speed needed for high-quality images. However, hardware is rapidly reaching its physical limitations in suppressing cardiac motion and represents a large financial investment. Today, software and AI are driving the next leap in cardiac image quality and motion control – offering […]

Cardiology Pharmaceuticals June 12, 2025

FDA Approves a New BP Triple Polypill June 12, 2025

Bringing a more effective BP therapy to the U.S. market, the FDA approved George Medicines’ triple therapy polypill called Widaplik for patients with hypertension, making it the first of its kind to go to market in the U.S. Widaplik’s approval stems from two studies, including one comparing the polypill against placebo as an initial treatment […]

Cardiology Pharmaceuticals June 12, 2025

Pharmacologic Preconditioning to Improve Outcomes in Patients Undergoing Cardiac Surgery  June 12, 2025

The majority of patients undergoing cardiac surgery, especially those on cardiopulmonary bypass (CPB), experience post-operative complications such as new-onset atrial fibrillation (POAF) and acute kidney injury (AKI), largely driven by oxidative stress and inflammation.   Several approaches have been explored to reduce complications following cardiac surgery, however, a clinically meaningful impact has yet to be realized.  […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!